Is Organogenesis Holdings Inc (ORGO) overvalued? · rev $81.0M
Organogenesis Holdings Inc (ORGO) is a drug manufacturers - specialty & generic company listed on NASDAQ.
This page asks whether Organogenesis Holdings Inc (ORGO) looks expensive on cached numbers — not a short thesis.
Latest reported ORGO revenue for 2026-06-30 was $81.0M. Net income was -$149.4M. ORGO currently screens at market cap $301.1M.
ORGO currently screens at market cap $301.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ORGO 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ORGO stock page for the full model, not this heading.
Not investment advice.